Folate metabolism in renal failure

Area of Science:

• Nephrology
• Hematology
• Nutritional Science

Background:

• Renal anemia in chronic kidney disease (CKD) is often managed with recombinant human erythropoietin (rHuEPO) and iron.
• Folate deficiency is a potential contributor to renal anemia and poor response to rHuEPO, prompting debate on routine supplementation.

Purpose of the Study:

• To evaluate the necessity and efficacy of folate supplementation in CKD patients.
• To identify specific patient groups who may benefit from folate supplementation.
• To assess the role of folate in managing hyperhomocysteinemia in dialysis patients.

Main Methods:

• Review of existing literature on folate status, supplementation, and outcomes in CKD patients.
• Analysis of diagnostic indicators for folate deficiency, including mean cell volume and leukocyte morphology.
• Evaluation of red blood cell (RBC) folate levels as a more accurate measure of tissue folate stores compared to serum folate.

Main Results:

• Routine folic acid supplementation is not beneficial for erythropoiesis or rHuEPO response in CKD patients without confirmed folate depletion.
• Folate deficiency should be suspected in CKD patients with macrocytosis, malnutrition, alcohol abuse history, or rHuEPO hyporesponsiveness.
• Low RBC folate levels indicate a need for supplementation and can help reduce elevated homocysteine levels in dialysis patients, potentially mitigating cardiovascular risk.

Conclusions:

• Folate supplementation should be guided by confirmed deficiency (ideally via RBC folate levels), not routine practice.
• Folic acid supplementation may offer cardiovascular benefits in dialysis patients by lowering homocysteine, though long-term outcomes require further study.
• Folic acid is generally safe and well-tolerated, especially when vitamin B12 status is adequate.